



REPORT PURSUANT TO SECTION 28a OF THE DANISH SECURITIES TRADING ACT

Copenhagen, Denmark; April 24, 2008 – Pursuant to Section 28a of the Danish Securities Trading Act, Genmab A/S (OMX: GEN) shall make public information on transactions by managerial employees and their related parties involving Genmab shares and related instruments, as follows:

Name: Jan G.J. van de Winkel
Reason: Member of the Management
Issuer: Genmab A/S
ID code/ ISIN: DK0010272202
Description: Warrants
Transaction: Grant
Trading date: April 24, 2008
Market: OMX Nordic Exchange Copenhagen A/S
Number: 50,000
Value: DKK 3,889,000

The exercise price for each warrant is DKK 254.00. Each warrant entitles the owner to subscribe one share of nominally DKK 1. On the basis of an exercise price of DKK 254.00 and by application of the Black-Scholes formula, the average value of each warrant can be calculated as DKK 77.78 based on an interest rate of 3.73% and the historical volatility of Genmab A/S shares calculated at 24.93%.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including

REPORT PURSUANT TO SECTION 28a OF THE DANISH SECURITIES TRADING ACT

unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab[®]; the Y-shaped Genmab logo[®]; HuMax[®]; HuMax-CD4[®]; HuMax-CD20[®]; HuMax-EGFr[™]; HuMax-IL8[™]; HuMax-TAC[™]; HuMax-HepC[™]; HuMax-CD38[™]; HuMax-CD32b[™] and UniBody[®] are all trademarks of Genmab A/S.

Contact: Helle Husted, Sr. Director, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: hth@genmab.com

###